Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Theratechnologies Inc. (T:TH)

Business Focus: Specialty & Advanced Pharmaceuticals

INK Edge Outlook

Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for TH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Oct 21, 2019 07:30 ET
Theratechnologies Provides Details About R&D Day Webcast
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (NASDAQ: THTX) (TSX: TH), a commercial-stage pharmaceutical company addressing unmet medical needs for people with orphan medical conditions, including those living with HIV, is pleased...
Read full article
Oct 14, 2019 10:49 ET
REMINDER - Tesamorelin Study Results on NAFLD Published in Lancet HIV
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX) is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.85
--
--
Price to Sales - TTM
4.59
30.58
11.16
Price to Book - most recent quarter
9.29
1.02
2.34
Price to Cash Flow per share - TTM
1,110.21
25.95
11.97
Price to Free Cash Flow per share - TTM
--
--
18.20
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Sep 30, 2019191,58013,357
Sep 15, 2019178,2232,294
Aug 31, 2019175,9293,541
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
INK Staff's picture
Since posting this free INK report Thursday, $ATH.CA is up 6.5%. Read about this Alberta ethical oil producer https://www.canadianinsider.com/featured-report/insiders-boost-holdings-trans-mountain-shipper-athabasca-oil
Jun 27, 2018 02:56 pm
INK Staff's picture
Since posting this free INK report Thursday, $ATH.CA is up 6.5%. Read about this Alberta ethical oil producer https://www.canadianinsider.com/featured-report/insiders-boost-holdings-trans-mountain-shipper-athabasca-oil
Jun 27, 2018 02:56 pm
Ted Dixon's picture
Wednesday's Morning INK stock Athabasca Oil $ATH.CA is up 6.3% today. Download the research report for free: https://www.canadianinsider.com/featured-report/insiders-boost-holdings-trans-mountain-shipper-athabasca-oil
Jun 22, 2018 12:49 pm
Ted Dixon's picture
Wednesday's Morning INK stock Athabasca Oil $ATH.CA is up 6.3% today. Download the report for free: https://www.canadianinsider.com/featured-report/insiders-boost-holdings-trans-mountain-shipper-athabasca-oil
Jun 22, 2018 12:48 pm
Ted Dixon's picture
Wednesday's Morning INK stock Athabasca Oil $ATH.CA is up 6.3% today. Download the report for free: https://www.canadianinsider.com/featured-report/insiders-boost-holdings-trans-mountain-shipper-athabasca-oil #OOTT
Jun 22, 2018 12:48 pm

Twitter

Search (past week) for $TH.CA

StockTwits